Description
B2M Knockout NFAT Luciferase Reporter Jurkat Cell Line | 78363 | Gentaur US, UK & Europe Disrtribition
Category: CAR-T/Cell Line
Application: Study the consequences of B2M knock down or use as control in immune-oncology product development.
Background: Beta-2-Microglobulin is a required component of Major Histocompatibility Complex (MHC) class 1 molecules, which present peptide fragments from within the cell to cytotoxic T cells as part of the adaptive immune system. The protein forms amyloid fibrils in some pathological conditions. A mutation in this gene drives hypercatabolic hypoproteinemia. B2M plays an essential role both in governing MHC class I molecule stability and in promoting antigen binding and presenting the antigen to CD3/TCR complex of CD8+ T cells. NFAT (Nuclear factor of activated T-cells) is a family of transcription factors that has an important function in immune responses, for example by inducing the expression of various cytokines (such as IL-2-3-4 and TNF-alpha) in T cells. NFAT is regulated by Ca2+ and the Ca2+/calmodulin-dependent serine phosphatase, calcineurin. NFAT is also activated by the T cell Receptor (TCR) in T cells.
Description: B2M (Beta-2-Microglobulin) has been genetically removed by CRISPR/Cas9 genome editing from NFAT Luciferase Reporter Jurkat cells. Expression of the firefly luciferase gene is driven by NFAT response elements located upstream of the minimal TATA promoter. Activation of the NFAT signaling pathway in these cells can be monitored by measuring luciferase activity.
Product Type: Cell Line
Shippement Condition: -80°C
